清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Liposomal Drug Delivery for Neurological Disorders: Advances and Challenges

脂质体 药品 药物输送 医学 药理学 纳米技术 材料科学
作者
Aysha Javed,Purba Mandal,Imran Khan,Aditya Pratap Singh,Juber Akhtar,Shubhrat Maheshwari,Bhupendra G. Prajapati
出处
期刊:Central nervous system agents in medicinal chemistry [Bentham Science Publishers]
卷期号:25 (3): 245-260 被引量:1
标识
DOI:10.2174/0118715249319942240903134353
摘要

Liposomal drug delivery methods are becoming increasingly viable options for improving treatment outcomes for neurological illnesses. These systems provide a flexible framework for the formulation of medications intended for delivery to the brain, protecting the medication from enzymatic breakdown and enhancing its bioavailability. To maximize liposome-drug interactions and improve brain-targeted delivery efficiency, a variety of formulation strategies are used, such as surface modification and remote loading. By utilizing various pathways to cross the blood- -brain barrier (BBB), such as passive diffusion and receptor-mediated transcytosis, liposomes facilitate the effective transport of therapeutic drugs to the brain parenchyma. Liposomal formulations show potential for targeted drug delivery, reducing off-target effects, and improving treatment efficacy in neurological conditions like Parkinson's disease, Alzheimer's disease, stroke, multiple sclerosis, and brain cancers. For instance, in Parkinson's disease, liposomal delivery of neuroprotective agents can help maintain dopamine levels and protect dopaminergic neurons. In Alzheimer's disease, liposomes can be engineered to deliver drugs that reduce amyloid-beta plaques or tau tangles. For brain cancer, liposomal chemotherapy can target tumor cells more precisely while minimizing damage to surrounding healthy tissue. In stroke, liposomal delivery of neuroprotective agents can reduce the extent of brain damage, while in multiple sclerosis, liposomes can be used to deliver drugs that modulate the immune response. However, the clinical translation of liposomal drug delivery systems for brain diseases faces challenges related to scalability, stability, and immunogenicity, in addition to regulatory barriers. Scalability issues arise from the complex manufacturing processes required to produce liposomes consistently on a large scale. Stability concerns involve maintaining the integrity of liposomes during storage and after administration. Immunogenicity can be a problem if the liposomes trigger an unwanted immune response, potentially reducing their effectiveness or causing adverse effects. To overcome these obstacles, multidisciplinary cooperation is essential. Collaboration among materials scientists, pharmacologists, neurologists, and regulatory experts can drive the development of more robust liposomal formulations. Continuous research is needed to refine liposome designs, such as by optimizing lipid composition, surface charge, and size to improve stability and targeting capabilities. Advanced techniques like PEGylation (coating liposomes with polyethylene glycol) can help reduce immunogenicity and extend circulation time in the bloodstream. Despite these challenges, liposomal methods present intriguing prospects for transforming medication administration to the brain and offering effective treatments for neurological illnesses. The development of more sophisticated liposomal technologies, combined with a deeper understanding of their mechanisms of action, could lead to significant breakthroughs in the treatment of neurological disorders. For example, research into ligand- targeted liposomes, which use specific molecules to bind to receptors on the BBB, holds promise for enhancing delivery specificity and efficiency. To fully realize the therapeutic promise of these novel drug delivery systems, further advancements in liposomal technologies and a deeper understanding of their mechanisms are necessary. This includes not only technical improvements but also comprehensive preclinical and clinical studies to evaluate safety, efficacy, and long-term effects. As our knowledge expands and technology progresses, liposomal drug delivery could become a cornerstone of neurological disease treatment, providing new hope for patients with previously intractable conditions.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
快乐舒完成签到 ,获得积分10
10秒前
n01W97的应助被科研通管家采纳,获得40
28秒前
无限的水香完成签到,获得积分10
46秒前
朴实水云完成签到,获得积分10
47秒前
Cakoibao的应助被dianeil采纳,获得10
56秒前
YYM完成签到 ,获得积分10
1分钟前
1分钟前
激情的盼晴完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
yanweihome完成签到 ,获得积分10
1分钟前
1分钟前
高高仰完成签到,获得积分10
1分钟前
2分钟前
缓慢忆灵完成签到,获得积分10
2分钟前
null的应助被科研通管家采纳,获得10
2分钟前
沉默的樱完成签到,获得积分10
2分钟前
五月完成签到,获得积分10
2分钟前
balko完成签到,获得积分10
2分钟前
高兴战斗机完成签到,获得积分10
2分钟前
2分钟前
suge完成签到,获得积分10
3分钟前
潇洒小海豚完成签到,获得积分10
3分钟前
笑点低的如萱完成签到,获得积分10
3分钟前
3分钟前
3分钟前
赖茜发布了新的文献求助10
3分钟前
xfy完成签到,获得积分10
4分钟前
务实的香薇完成签到,获得积分10
4分钟前
宝石完成签到,获得积分10
4分钟前
Maestro_S的应助被科研通管家采纳,获得20
4分钟前
4分钟前
4分钟前
复杂惜珊完成签到,获得积分10
4分钟前
u404711发布了新的文献求助10
4分钟前
激情的冰绿完成签到 ,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185376
求助须知:如何正确求助?哪些是违规求助? 9574120
关于积分的说明 21834329
捐赠科研通 7782804
什么是DOI,文献DOI怎么找? 3434552
关于科研通互助平台的介绍 2558824
邀请新用户注册赠送积分活动 2481272